Navigation Links
Regado Biosciences to Provide Second Quarter 2014 Financial Results and Corporate Highlights

BASKING RIDGE, N.J., July 29, 2014 /PRNewswire/ -- Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the Phase 3 clinical development of Revolixys™ Kit (previously known as REG1), its first-in-class, actively controllable antithrombotic drug system, today announced that it will hold a conference call and live audio webcast on Tuesday, Aug. 12, 2014, at 8:30 a.m. EDT to discuss its second quarter 2014 financial results and corporate highlights.

Interested participants and investors may access the conference call by dialing (877) 870-4263 for domestic callers or (412) 317-0790 for international callers. The conference call will be webcast live under the investor relations section of the Regado website at and will be archived there for 60 days following the call.


Regado Biosciences, Inc., is a biopharmaceutical company focused on the discovery and development of novel, oligonucleotide-based actively controllable therapeutics. Our initial focus is on applications in the acute and sub-acute cardiovascular therapeutic area. The company's lead product candidate, Revolixys™ Kit, is a two-component system consisting of pegnivacogin, an anticoagulant aptamer specifically targeting coagulation Factor IXa, and its complementary oligonucleotide active control agent, anivamersen. Revolixys™ Kit is currently being evaluated in the REGULATE-PCI trial, a worldwide Phase 3 trial comparing safety and efficacy of Revolixys Kit vs. bivalirudin in 13,200 patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI), a hospital-based procedure used to mechanically open or widen obstructed coronary arteries. Regado's actively controllable product candidates have the potential to improve patient outcomes and enhance the patient experience, provide direct therapeutic control to physicians and reduce overall treatment costs. More information can be found at

For more information on REGULATE-PCI, please visit:

Forward-Looking Statements:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to financial projections, estimates and their underlying assumptions, future performance, the progress of the REGULATE-PCI trial, enrollment in the REGULATE-PCI trial, the prospects for the completion of the REGULATE-PCI trial and any regulatory approval of Revolixys™ Kit and the successful commercialization of Revolixys™ Kit if approved. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from those projected in forward-looking statements include the outcome of the DSMB's currently ongoing analysis of REGULATE-PCI safety and efficacy data, the content of the DSMB's recommendations following such analysis, and the ultimate decision of the FDA to remove the clinical hold from the REGULATE-PCI trial, as well as the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 12, 2014, and in the Company's other periodic filings with the SEC. All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. The Company has no obligation, and expressly disclaims any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact:
Don Elsey, CFO
Regado Biosciences, Inc.

Media Contacts:
David Schull or Lena Evans
Russo Partners

SOURCE Regado Biosciences, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Regado Biosciences, Inc. to Present at the 2012 Wedbush PacGrow Life Sciences Conference in New York, NY
2. Regado Biosciences, Inc. to Present at the Canaccord Genuity 32nd Annual Growth Conference in Boston, MA
3. Regado Biosciences, Inc. to Present at the UBS Global Life Sciences Conference 2012 in New York, NY
4. Regado Biosciences, Inc. to Present at the Oppenheimer 23rd Annual Healthcare Conference in New York, NY
5. Regado Biosciences, Inc. Announces Pricing of Initial Public Offering
6. Regado Biosciences, Inc. Announces Closing of Initial Public Offering
7. Regado Biosciences, Inc. Announces Third Quarter 2013 Results
8. Regado Biosciences, Inc. Adds Global Pharmaceutical Business Veteran to Board of Directors
9. Regado Biosciences, Inc. Adds World-Class Interventional Cardiologist and Researcher to Medical Advisory Board
10. Attention Regado Biosciences, Inc. Investors: Regado Misled Investors According to a Recently Filed Class Action
11. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
Post Your Comments:
(Date:11/30/2015)... 30, 2015 Oramed Pharmaceuticals Inc. (NASDAQ: ... development of oral drug delivery systems, announced today it ... to $50,000,000 with Hefei Tianhui Incubator of Technologies Co., Ltd. ("HTIT") ... ORMD-0801, in China , ... . The agreements were signed at the Israel Knesset ...
(Date:11/30/2015)... -- Cumberland Pharmaceuticals (CPIX), today announced that A.J. Kazimi , ... 3, 2015. TIME: 3:15p.m. ET LINK: ... --> DATE: Thursday, December 3, ... --> --> This will be ... ask the company questions in real-time - both in the ...
(Date:11/30/2015)... , Nov. 30, 2015   Nuance Communications, ... The National Decision Support Company (NDSC) today jointly ... and collaboration capabilities that utilize the American College of ... healthcare provider organizations to comply with current and ... --> --> By combining clinical decision ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... According to Los Angeles bariatric surgeon ... are not necessarily caused by real hunger, but instead by a hormone called ... notes that, while many patients are aware that weight loss surgery can help patients ...
(Date:11/30/2015)... ... November 30, 2015 , ... RoamRight, a leading provider of ... Public Television’s Travel With Kids to promote family vacations around the world. ... they explore international destinations and educate families about the people and places of the ...
(Date:11/30/2015)... ... 30, 2015 , ... At Grand Dental PC, their priority is to deliver ... have dental problems, you need to turn to a dentist who listens and responds; ... needs, a friendly dentist who counsels you on the best ways to maintain and ...
(Date:11/30/2015)... ... ... Newly reviewed and approved “NJ Top Dentist”, Paul Dionne, ... both advanced training and considerable experience in reconstructive dentistry with attention to occlusal ... He is an active Spear Education member providing full mouth restorative and ...
(Date:11/30/2015)... ... ... ”Dying Words: The AIDS Reporting of Jeff Schmalz and How It Transformed ... World AIDS Day. The multi-media project will be in audio documentary form with a ... dying of the disease. , A collaborative effort led by author, professor and journalist ...
Breaking Medicine News(10 mins):